Upcoming Events
Past Events
|
May 11, 2022
10:00 AM EDT
|
|
|
May 10, 2022
12:40 PM PDT
|
|
|
Feb 16, 2022
8:00 AM EST
|
|
|
Nov 10, 2021
8:00 AM EST
|
|
|
Nov 8, 2021
10:30 AM EST
|
Galecto will host a key opinion leader event to discuss the current treatment landscape for NSCLC, as well as the potential for GB1211, Galecto’s galectin-3 inhibitor that is expected to enter a phase 2 trial in 1H 2022. |
|
Jun 9, 2021
|
Galecto will host a key opinion leader event to discuss the current treatment landscape and unmet clinical need for myelofibrosis, as well as the potential for GB2064, Galecto’s LOXL2 inhibitor that is expected to enter a phase 2 trial in the current quarter. |
|
Mar 30, 2021
|